Q4 2023 13F Holders as of 31 Dec 2023
-
Type / Class
-
Equity / Common Stock, par value $0.01 per share
-
Shares outstanding
-
183,255,226
-
Total 13F shares
-
112,451,511
-
Share change
-
-5,765,959
-
Total reported value
-
$191,165,565
-
Put/Call ratio
-
35%
-
Price per share
-
$1.70
-
Number of holders
-
149
-
Value change
-
+$1,074,277
-
Number of buys
-
70
-
Number of sells
-
52
Institutional Holders of HERON THERAPEUTICS, INC. /DE/ - Common Stock, par value $0.01 per share (HRTX) as of Q4 2023
As of 31 Dec 2023,
HERON THERAPEUTICS, INC. /DE/ - Common Stock, par value $0.01 per share (HRTX) was held by
149 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
112,451,511 shares.
The largest 10 holders included
Rubric Capital Management LP, VANGUARD GROUP INC, BlackRock Inc., Velan Capital Investment Management LP, FRANKLIN RESOURCES INC, Clearline Capital LP, ORBIMED ADVISORS LLC, Tejara Capital Ltd, PALISADE CAPITAL MANAGEMENT, LP, and ADAGE CAPITAL PARTNERS GP, L.L.C..
This page lists
149
institutional shareholders reporting positions in this security
for the Q4 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.